CAR T-cell Therapy in 2024

Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO

Recorded on March 12, 2024

Michael Tees, MD, MPH
Michael Tees, MD, MPH
Director, Lymphoma Program
Lymphoma Executive Committee Member, Sarah Cannon Research Institute
Associate Member, Colorado Blood Cancer Institute
Denver, CO
Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more!

This episode is supported by Bristol Myers Squibb, Johnson & Johnson|Legend Biotech, Kite, a Gilead Company, and Novartis Pharmaceuticals Corporation.

Leave a Reply

Your email address will not be published. Required fields are marked *